Mainz Biomed (MYNZ) announces that ColoAlert, its non-invasive colorectal cancer screening test, has been officially registered and approved for distribution by Swissmedic, the Swiss regulatory and supervisory authority for medicinal products and medical devices. The regulatory approval by Swissmedic follows the Company’s previously announced partnership with a local laboratory in Switzerland, labor team w ag, earlier this year. With this milestone, ColoAlert is now authorized for use in the Swiss market and will be made available through the partner laboratory’s diagnostic service offering, with no remaining obstacles to the upcoming launch.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYNZ:
- Mainz Biomed Secures $3 Million Through Securities Purchase Agreement
- Mainz Biomed files to sell 1.47M ordinary units
- Mainz Biomed, CARE announce collaboration agreement
- Mainz Biomed reviews accomplishments for first half of 2025
- Mainz Biomed secures public funding to advance pancreatic cancer screening test